title: Incidence and predictors of hospitalization for bacterial infection in community-based patients with type 2 diabetes: the fremantle diabetes study.
abstract: BACKGROUND
  The few studies that have examined the relationship between diabetes and bacterial infections have utilized administrative databases and/or have had limited/incomplete data including recognized infection risk factors. The aim of this study was to determine the incidence and associates of bacterial infection severe enough to require hospitalization in well-characterized community-based patients with type 2 diabetes.
  
  
  RESULTS
  We studied a cohort of 1,294 patients (mean±SD age 64.1±11.3 years) from the longitudinal observational Fremantle Diabetes Study Phase I (FDS1) and 5,156 age-, gender- and zip-code-matched non-diabetic controls. The main outcome measure was incident hospitalization for bacterial infection as principal diagnosis between 1993 and 2010. We also examined differences in statin use in 52 FDS1 pairs hospitalized with pneumonia (cases) or a contemporaneous non-infection-related cause (controls). During 12.0±5.4 years of follow-up, 251 (19.4%) patients were hospitalized on 368 occasions for infection (23.7/1,000 patient-years). This was more than double the rate in matched controls (incident rate ratio (IRR) (95% CI), 2.13 (1.88-2.42), P<0.001). IRRs for pneumonia, cellulitis, and septicemia/bacteremia were 1.86 (1.55-2.21), 2.45 (1.92-3.12), and 2.08 (1.41-3.04), respectively (P<0.001). Among the diabetic patients, older age, male sex, prior recent infection-related hospitalization, obesity, albuminuria, retinopathy and Aboriginal ethnicity were baseline variables independently associated with risk of first hospitalization with any infection (P≤0.005). After adjustment for these variables, baseline statin treatment was not significant (hazard ratio (95% CI), 0.70 (0.39-1.25), P = 0.22). Statin use at hospitalization for pneumonia among the case-control pairs was similar (23.1% vs. 13.5%, P = 0.27).
  
  
  CONCLUSIONS
  The risk of severe infection is increased among type 2 diabetic patients and is not reduced by statin therapy. There are a number of other easily-accessible sociodemographic and clinical variables that could be used to optimize infection-related education, prevention and management in type 2 diabetes.
authors.affiliation: Department of Endocrinology and Diabetes, Fremantle Hospital, Fremantle, Australia.
authors.forename: Emma J
authors.initials: EJ
authors.lastname: Hamilton
authors.forename: Natalie
authors.initials: N
authors.lastname: Martin
authors.forename: Ashley
authors.initials: A
authors.lastname: Makepeace
authors.forename: Brett A
authors.initials: BA
authors.lastname: Sillars
authors.forename: Wendy A
authors.initials: WA
authors.lastname: Davis
authors.forename: Timothy M E
authors.initials: TM
authors.lastname: Davis
mesh_terms: D000368:Aged; D001424:Bacterial Infections / Q000150:complications* / Q000453:epidemiology*; D017714:Community-Acquired Infections / Q000150:complications* / Q000453:epidemiology*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D005260:Female; D006760:Hospitalization; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects; D015994:Incidence; D008297:Male; D008875:Middle Aged; D011379:Prognosis
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
references.citation: Diabetes Care. 2004 Mar;27(3):752-7
references.pmid: 14988297
references.citation: Diabetes Care. 1980 Jan-Feb;3(1):187-97
references.pmid: 6996964
references.citation: Diabetologia. 2004 Mar;47(3):395-399
references.pmid: 14963648
references.citation: Nat Rev Endocrinol. 2010 Jan;6(1):43-7
references.pmid: 20010969
references.citation: Am J Med. 2002 Jul 8;113 Suppl 1A:80S-84S
references.pmid: 12113874
references.citation: JAMA. 1996 Jan 10;275(2):134-41
references.pmid: 8531309
references.citation: Med J Aust. 1991 Aug 19;155(4):218-22
references.pmid: 1875833
references.citation: Vaccine. 2011 Jul 26;29(33):5386-92
references.pmid: 21651943
references.citation: Int J Epidemiol. 1996 Dec;25(6):1172-81
references.pmid: 9027521
references.citation: Diabetes Care. 2005 Jul;28(7):1730-8
references.pmid: 15983327
references.citation: Fam Pract. 2010 Aug;27(4):379-85
references.pmid: 20462975
references.citation: Diabetes Care. 2012 Jan;35 Suppl 1:S11-63
references.pmid: 22187469
references.citation: Med Clin North Am. 1971 Jul;55(4):931-8
references.pmid: 5003919
references.citation: Diabetes Care. 2004 May;27(5):1143-7
references.pmid: 15111535
references.citation: Am J Epidemiol. 1993 May 1;137(9):977-88
references.pmid: 8317455
references.citation: Diabetes Care. 2002 Oct;25(10):1778-83
references.pmid: 12351477
references.citation: Infection. 2011 Oct;39(5):405-10
references.pmid: 21706223
references.citation: Diabetes Metab Res Rev. 2007 Jan;23(1):3-13
references.pmid: 16960917
references.citation: Eur J Endocrinol. 2012 Oct;167(4):589-99
references.pmid: 22893694
references.citation: Clin Infect Dis. 2007 Mar 1;44 Suppl 2:S27-72
references.pmid: 17278083
references.citation: J Antimicrob Chemother. 2008 Apr;61(4):774-85
references.pmid: 18263570
references.citation: Diabet Med. 2000 Sep;17(9):667-74
references.pmid: 11051287
references.citation: Diabet Med. 1992 May;9(4):354-8
references.pmid: 1600707
references.citation: Diabetes Care. 2003 Feb;26(2):510-3
references.pmid: 12547890
references.citation: Diabetes Care. 2008 Aug;31(8):1541-5
references.pmid: 18487479
references.citation: Aust N Z J Public Health. 1999 Oct;23(5):453-9
references.pmid: 10575763
references.citation: Clin Infect Dis. 2005 Aug 1;41(3):281-8
references.pmid: 16007521
references.citation: Arch Intern Med. 2009 Oct 12;169(18):1658-67
references.pmid: 19822822
references.citation: Postgrad Med J. 2011 Nov;87(1033):757-62
references.pmid: 21798969
references.citation: J Diabetes Complications. 2012 Nov-Dec;26(6):513-6
references.pmid: 22889712
references.citation: BMJ. 2012 May 28;344:e3397
references.pmid: 22645184
references.citation: Thorax. 2006 Nov;61(11):957-61
references.pmid: 16809409
references.citation: JAMA. 2005 Dec 7;294(21):2712-9
references.pmid: 16333006
references.citation: Crit Care. 2012 Aug 15;16(4):R155
references.pmid: 22894879
references.citation: Ann Pharmacother. 2007 Apr;41(4):647-52
references.pmid: 17389664
references.citation: Pulm Pharmacol Ther. 2013 Aug;26(4):412-9
references.pmid: 22634305
references.citation: Diabetologia. 2005 Jul;48(7):1288-91
references.pmid: 15918016
references.citation: J Diabetes Complications. 2005 Sep-Oct;19(5):259-63
references.pmid: 16112500
references.citation: Diabetes Care. 1994 Nov;17(11):1281-9
references.pmid: 7821168
references.citation: Endocr J. 2002 Oct;49(5):531-7
references.pmid: 12507271
references.citation: Clin Infect Dis. 2005 Nov 15;41 Suppl 7:S498-503
references.pmid: 16237653
references.citation: BMJ. 2011 Nov 29;343:d7281
references.pmid: 22127443
references.citation: Int J Epidemiol. 2013 Apr;42(2):412-21
references.pmid: 22544845
references.citation: J Bone Joint Surg Am. 2012 Jul 18;94(14):e101
references.pmid: 22810408
references.citation: Crit Care Med. 2004 Apr;32(4):992-7
references.pmid: 15071391
references.citation: J Infect. 2011 Jul;63(1):8-16
references.pmid: 21663970
references.citation: N Engl J Med. 1999 Dec 16;341(25):1906-12
references.pmid: 10601511
references.citation: BMJ Open. 2012 May 21;2(3):
references.pmid: 22614174
references.citation: Int J Epidemiol. 1997 Aug;26(4):797-805
references.pmid: 9279612
references.citation: Am J Geriatr Pharmacother. 2010 Dec;8(6):485-513
references.pmid: 21356502